Switch theme
Sign up to access all valuation multiples
Modus Therapeutics Holding AB is a Swedish clinical biotechnology company developing a treatment for sepsis, endotoxemia, severe malaria, and other disorders with severe systemic inflammation, as well as states of anemia related to chronic inflammation, such as kidney diseases, through its patented polysaccharide, sevuparin. The drug candidate sevuparin has the opportunity to benefit patients and save large healthcare costs.
2011
2
Last FY Revenue n/a
LTM EBITDA -$2.1M
$5.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Modus Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$2.1M.
In the most recent fiscal year, Modus Therapeutics achieved revenue of n/a and an EBITDA of -$1.6M.
Modus Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Modus Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$2.1M | XXX | -$1.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$2.1M | XXX | -$1.6M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$2.1M | XXX | -$1.6M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Modus Therapeutics's stock price is SEK 1 (or $0).
Modus Therapeutics has current market cap of SEK 53.9M (or $5.6M), and EV of SEK 53.6M (or $5.5M).
See Modus Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.5M | $5.6M | XXX | XXX | XXX | XXX | $-0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Modus Therapeutics has market cap of $5.6M and EV of $5.5M.
Modus Therapeutics's trades at n/a EV/Revenue multiple, and -3.4x EV/EBITDA.
Equity research analysts estimate Modus Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Modus Therapeutics has a P/E ratio of -2.7x.
See valuation multiples for Modus Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.6M | XXX | $5.6M | XXX | XXX | XXX |
| EV (current) | $5.5M | XXX | $5.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.7x | XXX | -3.4x | XXX | XXX | XXX |
| EV/EBIT | -2.7x | XXX | -3.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.7x | XXX | -3.5x | XXX | XXX | XXX |
| EV/FCF | -2.7x | XXX | -3.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialModus Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.8M for the same period.
Modus Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Modus Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Modus Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 39% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Modus Therapeutics acquired XXX companies to date.
Last acquisition by Modus Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Modus Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Modus Therapeutics founded? | Modus Therapeutics was founded in 2011. |
| Where is Modus Therapeutics headquartered? | Modus Therapeutics is headquartered in Sweden. |
| How many employees does Modus Therapeutics have? | As of today, Modus Therapeutics has 2 employees. |
| Is Modus Therapeutics publicy listed? | Yes, Modus Therapeutics is a public company listed on STO. |
| What is the stock symbol of Modus Therapeutics? | Modus Therapeutics trades under MODTX ticker. |
| When did Modus Therapeutics go public? | Modus Therapeutics went public in 2021. |
| Who are competitors of Modus Therapeutics? | Similar companies to Modus Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Modus Therapeutics? | Modus Therapeutics's current market cap is $5.6M |
| Is Modus Therapeutics profitable? | Yes, Modus Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Modus Therapeutics? | Modus Therapeutics's last 12 months EBITDA is -$2.1M. |
| What is the current EV/EBITDA multiple of Modus Therapeutics? | Current EBITDA multiple of Modus Therapeutics is -2.7x. |
| What is the current FCF of Modus Therapeutics? | Modus Therapeutics's last 12 months FCF is -$2.0M. |
| What is the current EV/FCF multiple of Modus Therapeutics? | Current FCF multiple of Modus Therapeutics is -2.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
